The December 2018 quarter revenue stood at Rs. 418.95 millions, up 10.08% as compared to Rs. 380.57 millions during the corresponding quarter last year.The Total Profit for the quarter ended December 2018 of Rs. 17.44 millions grew from Rs.-22.47 millions Operating profit Margin for the quarter ended December 2018 improved to 24.80% as compared to -20.44% of corresponding quarter ended December 2017 (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 418.95 380.57 10.08 1284.24 939.32 36.72 1266.04 1454.62 -12.96 Other Income 2.79 0.31 800.00 5.50 3.25 69.23 4.58 0.78 487.18 PBIDT 24.80 -20.44 -221.33 64.72 -95.48 -167.78 -106.50 62.37 -270.76 Interest 1.04 2.27 -54.19 4.72 6.05 -21.98 6.57 26.45 -75.16 PBDT 23.75 -22.71 -204.58 60.00 -101.53 -159.10 -113.07 163.90 -168.99 Depreciation 2.31 0.21 1000.00 7.35 3.05 140.98 3.20 19.94 -83.95 PBT 21.44 -22.93 -193.50 52.65 -104.59 -150.34 -116.27 143.96 -180.77 TAX 4.00 -0.46 -969.57 10.24 -1.38 -842.03 -0.76 25.31 -103.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 17.44 -22.47 -177.61 42.41 -103.20 -141.09 -115.51 118.65 -197.35 Equity 130.99 130.99 0.00 130.99 130.99 0.00 130.99 130.99 0.00 PBIDTM(%) 5.92 -5.37 -210.12 5.04 -10.16 -149.58 -8.41 4.29 -296.19

A decent increase of about 57.24% in the turnover to Rs. 424.04 millions was observed for the quarter ended June 2018. The turnover stood at Rs. 269.68 millions during the similar quarter previous year.The Total Profit for the quarter ended June 2018 of Rs. 7.27 millions grew from Rs.-42.20 millions Operating profit Margin for the quarter ended June 2018 improved to 13.33% as compared to -37.70% of corresponding quarter ended June 2017 (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201803 201703 % Var Sales 424.04 269.68 57.24 424.04 269.68 57.24 1266.04 1454.62 -12.96 Other Income 0.88 1.22 -27.87 0.88 1.22 -27.87 4.58 0.78 487.18 PBIDT 13.33 -37.70 -135.36 13.33 -37.70 -135.36 -106.50 62.37 -270.76 Interest 1.71 1.86 -8.06 1.71 1.86 -8.06 6.57 26.45 -75.16 PBDT 11.63 -39.56 -129.40 11.63 -39.56 -129.40 -113.07 163.90 -168.99 Depreciation 2.54 2.65 -4.15 2.54 2.65 -4.15 3.20 19.94 -83.95 PBT 9.09 -42.21 -121.54 9.09 -42.21 -121.54 -116.27 143.96 -180.77 TAX 1.82 0.00 0.00 1.82 0.00 0.00 -0.76 25.31 -103.00 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT 7.27 -42.20 -117.23 7.27 -42.20 -117.23 -115.51 118.65 -197.35 Equity 130.99 130.99 0.00 130.99 130.99 0.00 130.99 130.99 0.00 PBIDTM(%) 3.15 -13.98 -122.50 3.14 -13.98 -122.49 -8.41 4.29 -296.19

The sales slipped to Rs. 268.97 millions, down -33.16% for the June 2017 quarter as against Rs. 402.42 millions during the year-ago period.The Net Loss for the quarter ended June 2017 is Rs. -42.20 millions as compared to Net Profit of Rs. 6.41 millions of corresponding quarter ended June 2016Operating profit Margin for the quarter ended June 2017 slipped to -37.69% as compared to 24.55% of corresponding quarter ended June 2016 (Rs. in Million) Quarter ended Year to Date Year ended 201706 201606 % Var 201706 201606 % Var 201703 201603 % Var Sales 268.97 402.42 -33.16 268.97 402.42 -33.16 1442.61 1440.81 0.12 Other Income 1.22 0.00 0.00 1.22 0.00 0.00 0.78 0.64 21.88 PBIDT -37.69 24.55 -253.52 -37.69 24.55 -253.52 62.37 124.66 -49.97 Interest 1.86 9.49 -80.40 1.86 9.49 -80.40 26.45 52.97 -50.07 PBDT -39.55 15.06 -362.62 -39.55 15.06 -362.62 163.90 71.69 128.62 Depreciation 2.65 7.04 -62.36 2.65 7.04 -62.36 19.94 30.94 -35.55 PBT -42.20 8.02 -626.18 -42.20 8.02 -626.18 143.96 40.75 253.28 TAX 0.00 1.60 0.00 0.00 1.60 0.00 25.31 8.21 208.28 Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT -42.20 6.41 -758.35 -42.20 6.41 -758.35 118.65 32.54 264.63 Equity 130.99 130.99 0.00 130.99 130.99 0.00 130.99 130.99 0.00 PBIDTM(%) -14.01 6.10 -329.69 -14.01 6.10 -329.69 4.32 8.65 -50.03

Jagsonpal Pharmaceuticals has informed about the details of Voting results at the Extra Ordinary General Meeting (EGM) of the Company held on April 12, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015.The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharmaceuticals has informed that the Extra Ordinary General Meeting (EGM) of the Company was held on April 12, 2016.The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharmaceuticals has submitted a copy of Proceedings of the Meeting of the Board of Directors of the Company held on January 25, 2016.The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharmaceuticals has informed about authorised Key Managerial Personnel to determine materiality of events/information.The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharmaceuticals has informed that the Register of Members & Share Transfer Books of the Company will remain closed from September 23, 2015 to September 30, 2015 for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company to be held on September 30, 2015.The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharmaceuticals has informed about the Standalone Financial Results & a copy of the Limited Review Report for the period ended June 30, 2015.The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharmaceuticals has submitted a copy of Clause 20 as per the Listing Agreement for period ended March 31, 2015.The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharmaceuticals has informed that Pursuant to Regulation 8 & 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015, the Company has submitted the Code of Practices and procedures for fair disclosure of Unpublished Price Sensitive Information.The above information is a part of company’s filings submitted to BSE.

Jagsonpal Pharmaceuticals has submitted the disclosures under Reg.13 (6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.The above information is a part of company’s filings submitted to BSE